Avid Bioservices, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nicholas Stewart Green MBA
- Full Time Employees
- 371
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2642 Michelle Drive Tustin CA United States of America 92780
- IPO Date
- Apr 4, 1994
- CIK
- 0000704562
- Website
- avidbio.com
- Similar Companies
- Business
- Avid Bioservices, Inc. operates as a dedicated contract development and manufacturing organization (CDMO) specializing in the biotechnology and biopharmaceutical industries. The company provides comprehensive biopharmaceutical drug substance services including process development; current good manufacturing practice (CGMP) clinical and commercial manufacturing of biologics; mammalian cell culture production; bulk packaging; purification; release and stability testing; regulatory submission support; upstream and downstream process development and optimization; analytical methods development; cell line development; product characterization; and quality and regulatory compliance services. Avid Bioservices also offers specialized manufacturing capabilities in cell and gene therapy (CGT) with a state-of-the-art CGMP facility designed to produce suspension culture batches up to 3,000 liters and adherent cultures utilizing fixed bed bioreactors, supported by advanced filling and capping technology under isolators, and extensive quality control laboratory space. Founded in 1981 and headquartered in Tustin, California, Avid Bioservices has progressively expanded its capacity and service offerings, commissioning a mammalian protein CGMP drug substance Line 3 facility in 2023 and completing construction of new CGMP manufacturing suites dedicated to cell and gene therapy by early 2024, positioning the company to generate up to approximately $400 million in annual revenue. The company has a track record of producing over 250 commercial batches and 5 commercial products marketed in more than 90 countries, maintaining a flawless quality record for over a decade. Recently, in late 2024, Avid Bioservices was acquired in an all-cash transaction valued at approximately $1.1 billion by GHO Capital Partners and Ampersand Capital Partners, marking a major strategic shift to accelerate growth. This acquisition provides Avid with access to expanded capital, expertise, and networks aimed at enhancing service capabilities, scaling operations, and expanding geographic reach. The new ownership supports Avid’s focus on lifecycle manufacturing solutions spanning from concept through commercial supply, emphasizing investments in bioprocess optimization, analytical testing, regulatory compliance, and state-of-the-art manufacturing technologies. Avid Bioservices primarily serves biotechnology and pharmaceutical companies globally, operating within the healthcare and biotechnology sectors with a strong commitment to supporting complex biologics and advancing cell and gene therapy manufacturing capabilities. The company's evolution from a subsidiary of Peregrine Pharmaceuticals to an independent leading CDMO reflects its long-standing industry presence and forward-looking growth strategy under new ownership. This comprehensive suite of biologics manufacturing and development services combined with recent facility expansions and the strategic acquisition positions Avid Bioservices as a key player in the global CDMO market focused on innovative biologics and next-generation therapies.
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
Lifecore Biomedical to Participate at CDMO Live Europe
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
Leading CDMO Selects Kneat to Power Digital Validation Transformation
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer